Alzheimer's disease medications - Aricept
Professor Donna Wilcock explains that Aricept can only provide short-term benefit in treating Alzheimer's disease.
Most of the medications, in fact all of the medications right now that are FDA approved for Alzheimerâ€™s disease are really symptomatic and not really what we like to call disease-modifying. Aricept targets acetylcholine and essentially means that there is more acetylcholine in the brain to help with memory formation and memory recall. But this is really just a symptomatic treatment, and itâ€™s a temporary benefit that will last about six months, usually. After that six-month period, eventually that Alzheimerâ€™s patient is going to catch up to another Alzheimerâ€™s patient who has not received Aricept. So, it just gives a temporary benefit, which at this point is the best we can do. But itâ€™s only going to give you a short term benefit with your memory. The aim from a research standpoint is to really get to disease-modifying drugs that will modify either the amyloid plaques or neurofibrillary tangles and ultimately prevent the neuron loss that we think is causing the cognitive decline.
alzheimer, treatemnt, medication, aricept, cognitive, decline, memory, acetylcholine, brain, donna, wilcock
Professor Donna Wilcock dscusses the cholinergic hypothesis of Alzheimer's disease, which focuses on cholinergic neurons. The hypothesis has not been supported.
An overview of Alzheimer's disease-related content on Genes to Cognition Online.
Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.
Alzheimer’s disease is a progressive brain disorder that causes a gradual and irreversible loss of higher brain functions, including memory, language skills, and perception of time and space,
Professor Donna Wilcock discusses early-onset Alzheimer's disease, which can reach an advanced stage by the age of 50 or 60 years.
Professor Donna Wilcock discusses a new biological technique for diagnosing Alzheimer's disease using PET neuroimaging.
Professor Donna Wilcock describes the neuropathology of Alzheimer's disease as it progresses from the hippocampus to other brain areas.
Professor Donna Wilcock describes how neurofibrillary tangles choke neurons, causing them to die. This is one of three hallmarks of Alzheimer's disease.
Professor Donna Wilcock describes amyloid plaques as clumps of protein in the brain that are one of the three hallmarks of Alzheimer's disease.
Professor Donna Wilcock explains that neurotransmitter hypotheses of Alzheimer's disease are largely unspecific. Nevertheless, glutamate, serotonin, and NPY have elicited interest.